½ÃÀ庸°í¼­
»óǰÄÚµå
1372707

ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀå - ¼¼°è »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø(2018-2028³â) : ¿ëµµº°, Áö¿ªº°, °æÀï

Cold Plasma in Healthcare Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Application (Wound Healing, Surgical Application and Other Medical Applications), By Region and Competition

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: TechSci Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 183 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀåÀº 2022³â 18¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2028³â±îÁö ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 12.14%·Î ¿¹ÃøµÇ¸ç ¿¹Ãø ±â°£ µ¿¾È °­·ÂÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº ±¤¹üÀ§ÇÑ ÀÇ·á »ê¾÷¿¡¼­ ¿ªµ¿ÀûÀÌ°í ºü¸£°Ô ¹ßÀüÇÏ´Â ºÐ¾ß·Î ´Ù¾çÇÑ ÀÇ·á ¸ñÀû¿¡ Àú¿Â ÇöóÁ ±â¼úÀ» Àû¿ëÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ±× ¿ëµµ´Â »óó Ä¡À¯, ¾Ï Ä¡·á, »ì±Õ, ÇǺΰú µî ´Ù¾çÇÕ´Ï´Ù. Àú¿Â ÇöóÁ´Â ºñħ½ÀÀûÀÌ°í ºñ¿­ÀûÀΠƯ¼ºÀ¸·Î ÀÎÇØ ÀÇ·á ÇöÀå¿¡¼­ ´ÙÀç´Ù´ÉÇÑ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù. Á¶Á÷ Àç»ýÀ» ÃËÁøÇϰí, Ç÷°ü ½Å»ýÀ» ÃËÁøÇϸç, °Ç°­ÇÑ Á¶Á÷À» ¼Õ»ó½ÃŰÁö ¾Ê°í º´¿ø±ÕÀ» ¹Ú¸êÇÏ´Â µ¶Æ¯ÇÑ ´É·ÂÀº ÀÇ·áÁø, ¿¬±¸ÀÚ ¹× ¾÷°è °ü°èÀÚµé·ÎºÎÅÍ Å« °ü½ÉÀ» ¹Þ°í ÀÖ½À´Ï´Ù.

ÃÖ±Ù ¸î ³â µ¿¾È ´ç´¢º´, ¾Ï°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϸ鼭 ÀÌ ½ÃÀåÀº Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´¿¡´Â Çõ½ÅÀûÀ̰í È¿À²ÀûÀÎ Ä¡·á ¼Ö·ç¼ÇÀÌ ÇÊ¿äÇϸç, ƯÈ÷ »óó Ä¡·á¿¡¼­ Àú¿Â ÇöóÁ°¡ È¿°úÀûÀÓÀÌ ÀÔÁõµÇ°í ÀÖ½À´Ï´Ù. Àú¿Â ÇöóÁ´Â ´ç´¢º´¼º ±Ë¾ç°ú °°Àº ¸¸¼º »óó¿Í °°Àº ÀÇ·á ¹®Á¦¸¦ ÇØ°áÇÏ´Â µ¥ À¯¸ÁÇÕ´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2024-2028³â
2022³â ½ÃÀå ±Ô¸ð 18¾ï 9,000¸¸ ´Þ·¯
2028³â ½ÃÀå ±Ô¸ð 37¾ï 7,000¸¸ ´Þ·¯
CAGR 2023-2028³â 12.14%
±Þ¼ºÀå ºÎ¹® »óó Ä¡À¯
ÃÖ´ë ½ÃÀå ºÏ¹Ì

¶ÇÇÑ, COVID-19 ÆÒµ¥¹Í¿¡ ´ëÀÀÇϱâ À§ÇØ Àü ¼¼°èÀûÀ¸·Î °¨¿° ¿¹¹æ°ú ȯÀÚ ¾ÈÀü¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¸ê±Õ ¹× ¿À¿° Á¦°Å¸¦ À§ÇÑ Àú¿Â ÇöóÁ ±â¼ú µµÀÔÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå ÃËÁø¿äÀÎ

¸¸¼ºÁúȯÀÇ Áõ°¡

´ç´¢º´, ¾Ï°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¸Å¿ì Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. ¸¸¼º ÁúȯÀº Àü ¼¼°èÀûÀ¸·Î À¯ÇິÀÌ µÇ¾î ÀÇ·á ½Ã½ºÅÛ°ú ȯÀÚ¿¡°Ô Å« ºÎ´ãÀ» ÁÖ°í ÀÖ½À´Ï´Ù. Àú¿Â ÇöóÁ ±â¼úÀº ÀÌ·¯ÇÑ Áúº´ÀÇ °ü¸® ¹× Ä¡·á¿Í °ü·ÃµÈ ¸î °¡Áö ¹®Á¦¸¦ ÇØ°áÇÒ ¼ö ÀÖ´Â À¯¸ÁÇÑ ¼Ö·ç¼ÇÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

¸¸¼º Áúȯ¿¡¼­ Àú¿Â ÇöóÁÀÇ ÁÖ¿ä ÀÀ¿ë »ç·Ê Áß Çϳª´Â ƯÈ÷ ´ç´¢º´ ȯÀÚÀÇ »óó Ä¡À¯ÀÔ´Ï´Ù. ´ç´¢º´ ¼º ±Ë¾çÀº Á¾Á¾ Ä¡À¯°¡ Áö¿¬µÇ°í ÇÕº´ÁõÀ» À¯¹ßÇϱ⠽±½À´Ï´Ù. ¼¼Æ÷ Áõ½Ä°ú Ç÷°ü ½Å»ýÀ» ÀÚ±ØÇÏ´Â Àú¿Â ÇöóÁÀÇ ´É·ÂÀº ÀÌ·¯ÇÑ ¸¸¼º »óóÀÇ Ä¡À¯ °úÁ¤À» ÃËÁøÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Á¶Á÷ Àç»ýÀ» ÃËÁøÇÏ°í °¨¿° À§ÇèÀ» ÁÙÀÓÀ¸·Î½á Àú¿Â ÇöóÁ Ä¡·á´Â ´ç´¢º´ °ü·Ã ±Ë¾çÀ¸·Î °íÅë¹Þ´Â »ç¶÷µé¿¡°Ô Èñ¸ÁÀ»ÁÖ°í »îÀÇ ÁúÀ» °³¼±ÇÏ°í »çÁö Àý´Ü°ú °°Àº ´õ ½É°¢ÇÑ ÇÕº´ÁõÀ» ¿¹¹æÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Àü ¼¼°èÀûÀ¸·Î ¾Ï ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, È­Çпä¹ýÀ̳ª ¹æ»ç¼± Ä¡·á¿Í °°Àº ±âÁ¸ Ä¡·á¹ýÀº ħ½ÀÀûÀÌ°í ¼è¾àÇØÁú ¼ö ÀÖ½À´Ï´Ù. Àú¿Â ÇöóÁ ±â¼úÀº °Ç°­ÇÑ Á¶Á÷À» º¸Á¸Çϸ鼭 ¾Ï¼¼Æ÷¸¦ ¼±ÅÃÀûÀ¸·Î Ç¥ÀûÈ­ÇÏ¿© ÆÄ±«ÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ À¯¸ÁÇÕ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº ¾Ï Ä¡·áÀÇ È¿°ú¸¦ Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϰí ȯÀÚÀÇ Àü¹ÝÀûÀÎ °æÇèÀ» Çâ»ó½Ãŵ´Ï´Ù.

ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í

ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀåÀÇ ¼ºÀå°ú ¹ßÀü¿¡´Â 'ÀÇ·á¿¡ ´ëÇÑ ÀνÄÀÇ º¯È­'°¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Áö³­ ¸î ³â µ¿¾È ÀÇ·á Á¾»çÀÚ¿Í È¯ÀÚµé »çÀÌ¿¡¼­ ÀÇ·á¿¡ ´ëÇÑ ÀνÄÀÌ ´«¿¡ ¶ç°Ô º¯È­ÇÏ¿© Àú¿Â ÇöóÁ ±â¼úÀÇ ÀáÀçÀûÀÎ ÀÌÁ¡°ú ÀÀ¿ë¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁ³½À´Ï´Ù.

ù°, ÀÇ·áÁøÀº ´Ù¾çÇÑ ÀÇ·á ºÐ¾ß¿¡¼­ Àú¿Â ÇöóÁÀÇ ´Ù¾çÇÑ ÀÀ¿ë ºÐ¾ß¸¦ ÀνÄÇϰí ÀÖ½À´Ï´Ù. ¸ê±Õ, »óó Ä¡À¯, ¾Ï Ä¡·á, ÇǺΰú µîÀÇ Áø·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù´Â ÀνÄÀÌ È®»êµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ÀÇ·á ±â°üµéÀº ¿¬±¸°³¹ß, ÀÓ»ó½ÃÇè, Ä¡·á ÇÁ·ÎÅäÄÝ¿¡ Àú¿Â ÇöóÁ Àåºñ¸¦ ÅëÇÕÇÏ´Â µ¥ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, Àú¿Â ÇöóÁ ±â¼úÀÇ Ã¤ÅÃÀº ÀÇ·á ȯ°æ¿¡¼­ °ßÀηÂÀ» ¹ßÈÖÇϰí ÀÖ½À´Ï´Ù.

µÑ°, ÀÎÅͳݰú ¼Ò¼È ¹Ìµð¾î¸¦ ÅëÇÑ ÀÇ·á Á¤º¸ÀÇ È®»êÀ¸·Î ȯÀÚµéÀº ´ëüÀûÀ̰í Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇØ Á¡Á¡ ´õ ¸¹ÀÌ ¾Ë°Ô µÇ¾ú½À´Ï´Ù. ÀÌ¿¡ µû¶ó ´õ ³ªÀº Ä¡·á °á°ú¸¦ °¡Á®¿À°í ȯÀÚ °æÇèÀ» °³¼±ÇÏ´Â ±âÁ¸°ú´Â ´Ù¸¥ ÃÖ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ȯÀÚµéÀÌ ÀÚ½ÅÀÇ °Ç°­ °ü¸®¿¡ Àû±ØÀûÀ¸·Î Âü¿©ÇÔ¿¡ µû¶ó Àú¿Â ÇöóÁ ±â¼úÀ» Æ÷ÇÔÇÑ Ã·´Ü Ä¡·á¹ýÀ» Á¦°øÇÏ´Â ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¸¦ ã°Ô µÇ¾ú½À´Ï´Ù.

¶ÇÇÑ, COVID-19 »çÅ´ °¨¿° °ü¸®¿Í ȯÀÚ ¾ÈÀüÀÇ Á߿伺¿¡ ´ëÇÑ ÀÇ·á°èÀÇ ÀνÄÀ» ³ôÀÌ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çß½À´Ï´Ù. Àú¿Â ÇöóÁ°¡ Ç¥¸é°ú Àåºñ¸¦ ºü¸£°í ¾ÈÀüÇÏ°Ô ¸ê±ÕÇÏ´Â µ¥ È¿°úÀûÀ̶ó´Â »ç½ÇÀº À̹ø ÆÒµ¥¹Í ±â°£ µ¿¾È ´õ¿í ºÎ°¢µÇ¾ú°í, ÀÇ·á ±â°üµéÀÌ Àú¿Â ÇöóÁ µµÀÔÀ» °í·ÁÇÏ°Ô µÇ¾ú½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå °úÁ¦

ÀÇ·á¿ë ¿öÅ©Ç÷οì ÅëÇÕ

ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀåÀÌ Á÷¸éÇÑ °úÁ¦´Â ±âÁ¸ ÀÇ·á ¿öÅ©Ç÷ο쿡 Àú¿Â ÇöóÁ Àåºñ¸¦ ÅëÇÕÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ ±â¼úÀº Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖÁö¸¸, ÀÇ·á ½Ã¼³ÀÇ ÀÏ»ó°ú ¾÷¹«¿¡ ¿øÈ°ÇÏ°Ô ÅëÇÕÇÏ´Â µ¥´Â ¸î °¡Áö º¹ÀâÇÑ ¹®Á¦°¡ ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã¼³Àº È®¸³µÈ ÇÁ·ÎÅäÄݰú ÀýÂ÷¿¡ µû¶ó ¿î¿µµÇ°í ÀÖÀ¸¸ç, »õ·Î¿î ±â¼úÀÇ µµÀÔÀº È¿À²¼º°ú È¿°ú¸¦ º¸ÀåÇϱâ À§ÇØ ÀÌ·¯ÇÑ ¿öÅ©Ç÷ο쿡 ¸ÂÃç¾ß ÇÕ´Ï´Ù. ÅëÇÕÀÇ °úÁ¦´Â ÁÖ·Î ´ÙÀ½°ú °°Àº Á¡¿¡ ÀÖ½À´Ï´Ù.

ù°, ÀÇ·á ½Ã¼³Àº Àú¿Â ÇöóÁ Àåºñ¸¦ ¼ö¿ëÇϱâ À§ÇØ ÇÊ¿äÇÑ ÀÎÇÁ¶ó¿¡ ÅõÀÚÇØ¾ß ÇÕ´Ï´Ù. ¿©±â¿¡´Â °ø°£ ÇÒ´ç, Àü±âÀû ¿ä±¸ »çÇ×, Àú¿Â ÇöóÁ Àåºñ¿Í ±âÁ¸ ÀÇ·á Àåºñ ¹× ½Ã½ºÅÛ°úÀÇ ÅëÇÕ µîÀÇ °í·Á »çÇ×ÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ º¯È­´Â ¸¹Àº ÀÚ¿øÀ» ÇÊ¿ä·Î Çϱ⠶§¹®¿¡ ½ÅÁßÇÑ °èȹÀÌ ÇÊ¿äÇÕ´Ï´Ù.

µÑ°, Á÷¿ø ±³À°ÀÌ °¡Àå Áß¿äÇÕ´Ï´Ù. °£È£»çºÎÅÍ ±â¼úÀÚ, Àǻ翡 À̸£±â±îÁö ¸ðµç ÀÇ·á Àü¹®°¡´Â Àú¿Â ÇöóÁ ÀåºñÀÇ ÀÛµ¿ ¹× À¯Áöº¸¼ö¿¡ ´É¼÷ÇØ¾ß ÇÕ´Ï´Ù. ±³À° ÇÁ·Î±×·¥À» °³¹ß ¹× ½ÇÇàÇϰí ÀÇ·áÁøÀÌ Ç×»ó ÃֽЏð¹ü »ç·Ê¿¡ ´ëÇÑ ÃֽŠÁ¤º¸¸¦ ¾òÀ» ¼ö ÀÖµµ·Ï Áö¼ÓÀûÀÎ ±³À°ÀÌ ÇʼöÀûÀÔ´Ï´Ù.

¼Â°, »õ·Î¿î ±â¼úÀÇ µµÀÔÀº ±âÁ¸ ¿öÅ©Ç÷ο쿡 È¥¶õÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á ±â°üÀº ÀÌ·¯ÇÑ ÀüȯÀ» ½ÅÁßÇÏ°Ô °ü¸®ÇÏ¿© ȯÀÚ Ä¡·áÀÇ Áß´ÜÀ» ÃÖ¼ÒÈ­ÇØ¾ß ÇÕ´Ï´Ù. À̸¦ À§ÇØ ÀϽÃÀûÀ¸·Î º´·Ä ÇÁ·Î¼¼½º¸¦ º´ÇàÇϰųª Á¡ÁøÀûÀ¸·Î ÅëÇÕÇÏ¿© ¿øÈ°ÇÑ ÀüȯÀ» µµ¸ðÇØ¾ß ÇÕ´Ï´Ù.

¸¶Áö¸·À¸·Î, Àú¿Â ÇöóÁ ±â¼úÀ» ÅëÇÕÇÏ´Â µ¥´Â ºñ¿ëÀÌ µì´Ï´Ù. ÀÇ·á±â°üÀº Àåºñ ±¸¸Å, Á÷¿ø ±³À°, ÀÎÇÁ¶ó °³¼±¿¡ ¿¹»êÀ» ÅõÀÔÇØ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀçÁ¤Àû ºÎ´ãÀº ÀϺΠÀÇ·á ±â°ü, ƯÈ÷ ¼Ò±Ô¸ð ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿¡°Ô´Â Å« Àå¾Ö¹°ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

µµÀÔºñ¿ë

ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀåÀÇ °úÁ¦´Â µµÀÔ ºñ¿ëÀÔ´Ï´Ù. Àú¿Â ÇöóÁ ±â¼úÀÇ ÀåÁ¡Àº Á¡Á¡ ´õ ¸¹ÀÌ Àνĵǰí ÀÖÁö¸¸, ȹµæ, ÅëÇÕ ¹× ¿î¿µ¿¡ ÇÊ¿äÇÑ Ãʱâ ÅõÀÚ´Â ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿Í ÀÇ·á ±â°ü¿¡ Å« À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ù°, Àú¿Â ÇöóÁ Àåºñ ±¸¸Å¿¡ µå´Â Ãʱ⠺ñ¿ëÀÌ »ó´çÇÕ´Ï´Ù. °íǰÁú Àú¿Â ÇöóÁ Àåºñ´Â ÷´Ü ±â¼úÀÌ Àû¿ëµÈ Á¤¹Ð ±â±âÀ̸ç, Á¾Á¾ ±×¿¡ »óÀÀÇÏ´Â °¡°ÝÀÌ Ã¥Á¤µË´Ï´Ù. ¼Ò±Ô¸ð ÀÇ·á ½Ã¼³À̳ª ¿¹»êÀÌ Á¦ÇÑµÈ ½Ã¼³¿¡¼­´Â Ãʱ⠱¸¸Å¿¡ ÀÚ¿øÀ» ÇÒ´çÇϱ⠾î·Á¿ï ¼ö ÀÖ½À´Ï´Ù.

µÑ°, ±¸¸Å ºñ¿ë»Ó¸¸ ¾Æ´Ï¶ó Áö¼ÓÀûÀÎ ¿î¿µ ºñ¿ëµµ °í·ÁÇØ¾ß ÇÕ´Ï´Ù. ¿©±â¿¡´Â Àú¿Â ÇöóÁ Àåºñ°¡ ÃÖÀûÀ¸·Î ÀÛµ¿ÇÒ ¼ö ÀÖµµ·Ï À¯Áöº¸¼ö, ±³Á¤, Á¤±âÀûÀÎ À¯Áöº¸¼ö ¹× Á¡°ËÀÌ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ, °¡½º °ø±Þ°ú °°Àº ¼Ò¸ðǰ ºñ¿ëÀº ÃÑ µµÀÔ ºñ¿ëÀ» Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Àú¿Â ÇöóÁ ±â¼ú¿¡ ´ëÀÀÇϱâ À§ÇØ ÀÎÇÁ¶ó ¹× ½Ã¼³¿¡ ´ëÇÑ ÅõÀÚ°¡ ÇÊ¿äÇÒ ¼öµµ ÀÖ½À´Ï´Ù. Àú¿Â ÇöóÁ ÀåºñÀÇ Àü±âÀû ¹× °ø°£Àû ¿ä±¸ »çÇ×À» ÃæÁ·½Ã۱â À§ÇØ ±âÁ¸ ÀÇ·á ȯ°æÀ» º¯°æÇÏ´Â °ÍÀº °æÁ¦Àû ºÎ´ãÀÇ ¿øÀÎÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

ÀÇ·á ¼­ºñ½º Á¦°øÀÚ´Â Á÷¿ø ÈÆ·Ã°ú ±³À°¿¡µµ ÀÚ¿øÀ» ÅõÀÚÇØ¾ß ÇÕ´Ï´Ù. ÀÇ·áÁøÀÌ Àú¿Â ÇöóÁ ÀåºñÀÇ »ç¿ë ¹× À¯Áöº¸¼ö¿¡ ´É¼÷ÇÑÁö È®ÀÎÇÏ´Â °ÍÀº ¾ÈÀüÇϰí È¿°úÀûÀÎ ¿î¿µÀ» À§ÇØ ÇʼöÀûÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå µ¿Çâ

µ¥ÀÌÅÍ ÁÖµµÇü ÀÇ·á

ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀåÀÇ ÁÖ¿ä Æ®·»µå´Â µ¥ÀÌÅÍ ±â¹Ý ÀÇ·á°¡ Áß½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ Ãß¼¼´Â Ä¡·áÀÇ Á¤È®¼º°ú È¿°ú¸¦ ³ôÀ̱â À§ÇØ Àú¿Â ÇöóÁ Àåºñ¿Í ÷´Ü µ¥ÀÌÅÍ ¼öÁý ¹× ºÐ¼® ½Ã½ºÅÛÀ» ÅëÇÕÇÏ´Â °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù.

¿À´Ã³¯ÀÇ ÀÇÇп¡¼­ µ¥ÀÌÅÍ´Â ¿ÕÀÔ´Ï´Ù. Àú¿Â ÇöóÁ ±â¼úµµ ¿¹¿Ü´Â ¾Æ´Õ´Ï´Ù. °¢ Á¦Á¶¾÷ü´Â Àú¿Â ÇöóÁ Àåºñ¿¡ ¼¾¼­¿Í ¸ð´ÏÅ͸µ ±â´ÉÀ» ³»ÀåÇÏ¿© Ä¡·á Áß ½Ç½Ã°£ µ¥ÀÌÅÍ ¼öÁýÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÀÌ µ¥ÀÌÅÍ¿¡´Â ¿Âµµ, °¡½º À¯·®, Ä¡·á ½Ã°£ µîÀÇ ÆÄ¶ó¹ÌÅͰ¡ Æ÷ÇԵ˴ϴÙ. ¼öÁýµÈ Á¤º¸´Â Áß¾Ó ½Ã½ºÅÛÀ̳ª Ŭ¶ó¿ìµå Ç÷§ÆûÀ¸·Î Àü¼ÛµÇ¾î ºÐ¼® ¹× ÇØ¼®µË´Ï´Ù.

Àú¿Â ÇöóÁÀÇ µ¥ÀÌÅÍ ±â¹Ý ÀÇ·á ÇýÅÃÀº ¸Å¿ì Å®´Ï´Ù. ÀÇ·áÁøÀº ȯÀÚº° µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î Ä¡·á¸¦ ¸é¹ÐÈ÷ ¸ð´ÏÅ͸µÇϰí Á¶Á¤ÇÏ¿© Ä¡·á °á°ú¸¦ ÃÖÀûÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, »óó Ä¡À¯¿¡¼­ µ¥ÀÌÅÍ ±â¹Ý ½Ã½ºÅÛÀº Àú¿Â ÇöóÁ Ä¡·á¿¡ ´ëÇÑ Á¶Á÷ÀÇ ¹ÝÀÀÀ» Æò°¡Çϰí Ä¡À¯ ¼Óµµ¸¦ ³ôÀ̱â À§ÇØ ½Ç½Ã°£À¸·Î Á¶Á¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾Ï Ä¡·á¿¡¼­´Â Ä¡·á È¿°ú¸¦ ¸é¹ÐÈ÷ ¸ð´ÏÅ͸µÇÏ¿© Àú¿Â ÇöóÁ°¡ °Ç°­ÇÑ Á¶Á÷À» º¸Á¸Çϸ鼭 ¾Ï¼¼Æ÷¸¦ Á¤È®ÇÏ°Ô Ç¥ÀûÀ¸·Î »ï°í ÀÖ´ÂÁö È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¼öÁýµÈ µ¥ÀÌÅÍ´Â ¿¬±¸ °³¹ß¿¡ ±â¿©Çϰí Àú¿Â ÇöóÁ ±â¼ú°ú ÀÇ·á ÀÀ¿ë ºÐ¾ßÀÇ Áö¼ÓÀûÀÎ °³¼±À» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¾ò°í ÀÇ·á Àü¹®°¡µé »çÀÌ¿¡¼­ ½Å·Ú¸¦ ±¸ÃàÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ Áõ°Å¿¡ ±â¹ÝÇÑ ÀÇ»ç°áÁ¤À» Áö¿øÇÕ´Ï´Ù.

ÀÌ·¯ÇÑ Ãß¼¼´Â ÀÇ·á µðÁöÅÐÈ­¸¦ ÇâÇÑ ±¤¹üÀ§ÇÑ ¿òÁ÷ÀÓ°ú ÀÏÄ¡Çϸç, Ä¡·á Á¤È®µµ Çâ»ó, ȯÀÚ ¾ÈÀü, º¸´Ù È¿°úÀûÀÌ°í °³ÀÎÈ­µÈ ÀÇ·á °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. µ¥ÀÌÅÍ ±â¹Ý Á¢±Ù ¹æ½ÄÀÌ È®»êµÊ¿¡ µû¶ó Àú¿Â ÇöóÁ ±â¼úÀÌ Çö´ë ÀÇÇп¡¼­ ±ÍÁßÇÑ µµ±¸·Î¼­ ¿ªÇÒÀ» ´õ¿í °­È­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°³º°È­ ÀÇ·á

ÀÇ·á ½ÃÀå¿¡¼­ °³ÀÎ ¸ÂÃãÇü ÀÇ·á´Â °³ÀÎÀÇ Æ¯¼º, ÇÊ¿ä, À¯ÀüÀÚ ÇÁ·ÎÇÊ¿¡ µû¶ó ÀÇ·á °³ÀÔÀ» ¸ÂÃãÈ­Çϴ ȯÀÚ °ü¸® ¹× Ä¡·á¿¡ ´ëÇÑ Çõ½ÅÀû Á¢±Ù ¹æ½ÄÀ» ÀǹÌÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ÀÇ·á ¼Ö·ç¼Ç Á¦°ø¿¡ ÀÖ¾î Á¤È®¼º°ú ¸ÂÃãÈ­¿¡ ÁßÁ¡À» µÎ¸é¼­ ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀåÀ» ÀçÆíÇϰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡¼­´Â ȯÀÚÀÇ À¯ÀüÀû Ư¼º°ú º´·Â¿¡ µû¶ó Ä¡·á¿Í ¿ä¹ýÀ» Á¤È®ÇÏ°Ô ¼³°èÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº º¸´Ù Ç¥ÀûÈ­µÇ°í È¿°úÀûÀÎ °³ÀÔÀ» °¡´ÉÇÏ°Ô Çϰí, ºÎÀÛ¿ëÀÇ À§ÇèÀ» ÁÙÀ̸ç, Ä¡·á °á°ú¸¦ ÃÖÀûÈ­ÇÕ´Ï´Ù. ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀåÀÇ °æ¿ì, ÀÌ´Â »óó Ä¡À¯, ¾Ï Ä¡·á ¹× ±âŸ ÀÀ¿ë ºÐ¾ß¿¡¼­ Àú¿Â ÇöóÁ ±â¼úÀ» °¢ ȯÀÚÀÇ Æ¯Á¤ ¿ä±¸»çÇ׿¡ ¸Â°Ô ¹Ì¼¼ Á¶Á¤ÇÒ ¼ö ÀÖ´Ù´Â °ÍÀ» ÀǹÌÇÕ´Ï´Ù. ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ È¿°úÀûÀÏ »Ó¸¸ ¾Æ´Ï¶ó ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ°í ¼º°ø °¡´É¼ºÀ» ±Ø´ëÈ­ÇÒ ¼ö ÀÖ´Â Ä¡·á¹ýÀ» ã´Â °æÇâÀÌ ³ô¾ÆÁü¿¡ µû¶ó °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àú¿Â ÇöóÁÀÇ ÀûÀÀ¼º°ú ´ÙÀç´Ù´ÉÇÔÀº ȯÀÚ °³°³ÀÎÀÇ Çʿ信 ¸Â°Ô Á¶Á¤Çϰí ÃÖÀûÈ­ÇÒ ¼ö Àֱ⠶§¹®¿¡ ÀÌ·¯ÇÑ Ãß¼¼¿¡ ÀûÇÕÇÕ´Ï´Ù. ¶ÇÇÑ, ¸ÂÃãÇü ÀÇ·á´Â ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀåÀÇ ¿¬±¸°³¹ßÀ» ÃËÁøÇÒ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ȯÀÚ °á°ú¿Í Ä¡·á ¹ÝÀÀ¿¡ ´ëÇÑ ´õ ¸¹Àº µ¥ÀÌÅͰ¡ ¼öÁýµÇ¸é Àú¿Â ÇöóÁ ±â¼ú°ú ±× Àû¿ëÀ» °³¼±ÇÏ¿© º¸´Ù È¿°úÀûÀ̰í ȯÀÚ Áß½ÉÀÇ ¼Ö·ç¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù.

ºÎ¹®º° ÀλçÀÌÆ®

¿ëµµº° ÀλçÀÌÆ®

ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀåÀº »óó Ä¡·á ºÐ¾ß°¡ Áö¹èÀûÀ̸ç, ÇâÈÄ¿¡µµ °è¼Ó È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀå¿¡¼­ »óó Ä¡À¯ ºÎ¹®ÀÇ ¿ìÀ§´Â ¸î °¡Áö ¼³µæ·Â ÀÖ´Â ¿äÀÎÀ¸·Î ÀÎÇØ Áö¼ÓÀûÀ¸·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ´Â ¼±µÎ ÁÖÀÚÀÔ´Ï´Ù. ù°, ´ç´¢º´¼º ±Ë¾çÀ̳ª ¿åâ°ú °°Àº ¸¸¼º »óó´Â Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ´Â ÀÇ·á ¹®Á¦ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ »óȲ¿¡¼­ Çõ½ÅÀûÀ̰í È¿°úÀûÀÎ »óó Ä¡·á ¼Ö·ç¼ÇÀÌ ¿ä±¸µÇ°í ÀÖÀ¸¸ç, Àú¿Â ÇöóÁ ±â¼úÀÌ À¯¸ÁÇÑ ÇØ´äÀ¸·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. Àú¿Â ÇöóÁ´Â °¨¿° À§ÇèÀ» ÃÖ¼ÒÈ­Çϸ鼭 ¼¼Æ÷ Áõ½Ä, Ç÷°ü ½Å»ý ¹× Á¶Á÷ Àç»ýÀ» ÀÚ±ØÇÏ¿© »óó Ä¡À¯¸¦ ÃËÁøÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¶Ù¾î³­ Ä¡·á ´É·ÂÀº ÀÇ·áÁø°ú ¿¬±¸ÀÚµé·ÎºÎÅÍ Å« ÁÖ¸ñÀ» ¹Þ°í ÀÖ½À´Ï´Ù. µÑ°, Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ ºñ¿ë È¿À²ÀûÀ̰í È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» ã°í ÀÖ´Â °¡¿îµ¥, »óó Ä¡·á¿¡¼­ Àú¿Â ÇöóÁÀÇ ¿ªÇÒÀÌ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. Ä¡À¯ °úÁ¤À» ÃËÁøÇϰí ÇÕº´Áõ À§ÇèÀ» ÁÙÀÓÀ¸·Î½á ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó Àå±âÀûÀ¸·Î ºñ¿ë Àý°¨¿¡µµ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á±â°üµéÀº Àú¿Â ÇöóÁ Àåºñ µµÀÔÀÇ °æÁ¦Àû ÀÌÁ¡À» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19 »çÅ´ ¹«±Õ ÀÇ·á ȯ°æ À¯Áö¿Í È¿À²ÀûÀÎ »óó Ä¡·áÀÇ Á߿伺À» ºÎ°¢½ÃÄÑ Àú¿Â ÇöóÁ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½ÃÄ×½À´Ï´Ù. ÀÇ·á ¹× Å¬¸®´ÐÀº °¨¿° °ü¸® ¹× »óó Ä¡·áÀÇ È¿°úÀûÀÎ ¼ö´ÜÀ» ã°í ÀÖÀ¸¸ç, Àú¿Â ÇöóÁ ±â¼úÀº ÀÇ·á ÇöÀå¿¡¼­ Áß¿äÇÑ ÀÚ»êÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Áö¿ªº° ÀλçÀÌÆ®

ºÏ¹Ì Áö¿ªÀº 2022³â ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀåÀÇ ¼±µÎÁÖÀÚ·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ¿ì¼±, ºÏ¹Ì´Â ÃÖ÷´Ü ÀÇ·á ½Ã¼³, ¿¬±¸ ±â°ü ¹× ±â¼úÀûÀ¸·Î Áøº¸µÈ ÀÇ·á ºÎ¹®À» Æ÷ÇÔÇÑ °ß°íÇϰí È®¸³µÈ ÀÇ·á ÀÎÇÁ¶ó¸¦ ÀÚ¶ûÇÕ´Ï´Ù. ÀÌ´Â Àú¿Â ÇöóÁ¿Í °°Àº Çõ½ÅÀûÀÎ ±â¼úÀ» ÀÇ·á ÁÖ·ù¿¡ µµÀÔÇϰí ÅëÇÕÇÏ´Â µ¥ ÀûÇÕÇÑ È¯°æÀ» Á¦°øÇÕ´Ï´Ù. µÑ°, ÀÌ Áö¿ªÀÇ ÀÇ·á ¹ßÀü°ú ȯÀÚ ¾ÈÀüÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Àú¿Â ÇöóÁ ±â¼úÀÌ ºü¸£°Ô È®»êµÇ°í ÀÖ½À´Ï´Ù. ºÏ¹ÌÀÇ ÀÇ·á ¼­ºñ½º Á¦°øÀÚµéÀº ƯÈ÷ COVID-19 ÆÒµ¥¹Í »óȲ¿¡¼­ ¸ê±Õ, »óó Ä¡À¯, ¾Ï Ä¡·á¿¡¼­ Àú¿Â ÇöóÁÀÇ ÀÌÁ¡À» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Àú¿Â ÇöóÁ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¼Â°, ºÏ¹ÌÀÇ ±ÔÁ¦ ȯ°æÀº ÀÇ·á±â¼úÀÇ ½ÂÀΰú Ãâ½Ã¿¡ ´ëÇÑ ¸íÈ®ÇÑ ±æÀ» Á¦½ÃÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ FDA¿Í °°Àº ±ÔÁ¦ ±â°üÀº Àú¿Â ÇöóÁ ÀåÄ¡ÀÇ Æò°¡¿Í ½ÂÀο¡ Àû±ØÀûÀ¸·Î ³ª¼­°í ÀÖÀ¸¸ç, ÀÇ·á ¼­ºñ½º Á¦°øÀÚµéÀº ±× ¾ÈÀü¼º°ú È¿°ú¿¡ ´ëÇÑ ½Å·Ú¸¦ °®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºÏ¹Ì¿¡¼­´Â Çаè, »ê¾÷°è, ÀÇ·á ¼­ºñ½º Á¦°øÀÚ °£ÀÇ Çù·ÂÀ» ÅëÇØ ±â¼ú Çõ½Å°ú Áö½Ä °øÀ¯¸¦ ÃËÁøÇÏ¿© ´Ù¾çÇÑ ÀÇ·á¿ë Àú¿Â ÇöóÁ ±â¼úÀÇ °³¹ß ¹× µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå °í°´ÀÇ ¼Ò¸®

Á¦5Àå ÀÇ·á¿ë Àú¿Â ÇöóÁ ¼¼°è ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • ¿ëµµº°(â»ó Ä¡À¯, ¿Ü°ú ¿ëµµ, ±âŸ ÀÇ·á ¿ëµµ)
    • Áö¿ªº°
    • ±â¾÷º°(2022³â)
  • ½ÃÀå ¸Ê

Á¦6Àå ºÏ¹ÌÀÇ ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • ¿ëµµº°
    • ±¹°¡º°
  • ºÏ¹Ì : ±¹°¡º° ºÐ¼®
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ

Á¦7Àå À¯·´ÀÇ ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • ¿ëµµº°
    • ±¹°¡º°
  • À¯·´ : ±¹°¡º° ºÐ¼®
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • ¿ëµµº°
    • ±¹°¡º°
  • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º° ºÐ¼®
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ

Á¦9Àå ³²¹ÌÀÇ ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • ¿ëµµº°
    • ±¹°¡º°
  • ³²¹Ì : ±¹°¡º° ºÐ¼®
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÇ·á¿ë Àú¿Â ÇöóÁ ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • ¿ëµµº°
    • ±¹°¡º°
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ºÐ¼®
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®

Á¦11Àå ½ÃÀå ¿ªÇÐ

  • ¼ºÀå ÃËÁø¿äÀÎ
  • °úÁ¦

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

  • ÃÖ±ÙÀÇ Àü°³
  • ÀμöÇÕº´

Á¦13Àå ÀÇ·á¿ë Àú¿Â ÇöóÁ ¼¼°è ½ÃÀå SWOT ºÐ¼®

Á¦14Àå Porter's Five Forces ºÐ¼®

  • ¾÷°è³» °æÀï
  • ½Å±Ô Âü¿© °¡´É¼º
  • °ø±Þ¾÷üÀÇ ´É·Â
  • °í°´ÀÇ ´É·Â
  • ´ëüǰÀÇ À§Çù

Á¦15Àå °æÀï »óȲ

  • Neoplas med GmbH
  • U.S. Medical Innovations
  • Terumo Medical Corp
  • Adtec Plasma Technology Co Ltd
  • Apyx Medical Corp
  • Nordson Corp
  • Europlasma NV
  • Terraplasma GmbH
  • Henniker Plasma
  • Smith & Nephew plc

Á¦16Àå Àü·«Àû Á¦¾È

Á¦17Àå Á¶»ç ȸ»ç ¼Ò°³ ¹× ¸éÃ¥»çÇ×

ksm 23.11.08

The Cold Plasma in Healthcare Market, valued at USD 1.89 Billion in 2022, is poised for robust growth in the forecast period, with an anticipated Compound Annual Growth Rate (CAGR) of 12.14% through 2028.

This market represents a dynamic and rapidly evolving sector within the broader healthcare industry, focused on applying cold plasma technology for various medical purposes. These applications span wound healing, cancer treatment, sterilization, and dermatology. Cold plasma stands out due to its non-invasive and non-thermal nature, making it a versatile tool in medical settings. Its unique ability to stimulate tissue regeneration, promote angiogenesis, and eradicate pathogens without harming healthy tissues has garnered significant attention from healthcare providers, researchers, and industry players.

Recent years have witnessed substantial growth in this market, primarily driven by the increasing prevalence of chronic diseases like diabetes and cancer. These conditions demand innovative and efficient treatment solutions, and cold plasma has proven effective, particularly in wound care. It has shown promise in addressing challenging healthcare needs, such as chronic wounds like diabetic ulcers.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1.89 Billion
Market Size 2028USD 3.77 Billion
CAGR 2023-202812.14%
Fastest Growing SegmentWound Healing
Largest MarketNorth America

Furthermore, the global emphasis on infection control and patient safety, particularly in response to the COVID-19 pandemic, has accelerated the adoption of cold plasma technology for sterilization and decontamination purposes.

The Cold Plasma in Healthcare market also benefits from collaborative research efforts involving academia, industry, and healthcare providers. These collaborations facilitate innovation and knowledge sharing. As the market continues to expand, it is expected to encompass a broader range of medical specialties, offering personalized and precision treatments. With regulatory support, ongoing technological advancements, and increasing healthcare awareness, cold plasma technology is poised to play an increasingly pivotal role in improving patient outcomes and safety. This makes it an exciting and promising sector for stakeholders and investors in the healthcare arena.

Key Market Drivers

Increasing Chronic Diseases

The increasing prevalence of chronic diseases, such as diabetes and cancer, is a pivotal factor driving the growth of the Cold Plasma in Healthcare market. Chronic diseases have become a global health epidemic, imposing significant burdens on healthcare systems and patients alike. Cold plasma technology has emerged as a promising solution to address some of the challenges associated with the management and treatment of these conditions.

One of the primary applications of cold plasma in the context of chronic diseases is in wound healing, particularly for individuals with diabetes. Diabetic ulcers, often slow to heal and prone to complications, are a common consequence of the disease. Cold plasma's ability to stimulate cell proliferation and angiogenesis plays a critical role in expediting the healing process for such chronic wounds. By enhancing tissue regeneration and reducing infection risk, cold plasma therapy offers hope to individuals suffering from diabetes-related ulcers, improving their quality of life and potentially preventing more severe complications like limb amputations.

Moreover, the prevalence of cancer is on the rise globally, and traditional treatment modalities like chemotherapy and radiation therapy can be invasive and debilitating. Cold plasma technology has shown promise in the selective targeting and destruction of cancer cells while sparing healthy tissue. This approach not only improves the effectiveness of cancer treatment but also minimizes side effects, enhancing the overall patient experience.

Rising Healthcare Awareness

The factor of "Rising Healthcare Awareness" plays a crucial role in the growth and evolution of the Cold Plasma in the Healthcare market. Over the past few years, there has been a notable shift in healthcare awareness among both healthcare providers and patients, leading to increased recognition of the potential benefits and applications of cold plasma technology.

Firstly, healthcare providers are becoming more aware of the diverse applications of cold plasma in various medical fields. They are recognizing its potential to revolutionize practices in sterilization, wound healing, cancer treatment, dermatology, and beyond. This heightened awareness has prompted healthcare institutions to invest in research and development, clinical trials, and the integration of cold plasma devices into their treatment protocols. As a result, the adoption of cold plasma technology has gained traction within healthcare settings.

Secondly, patients are increasingly informed about alternative and innovative treatment options, thanks to the proliferation of healthcare information through the internet and social media. This has led to a growing demand for non-traditional, cutting-edge therapies that offer better outcomes and improved patient experiences. As patients become more proactive in managing their health, they are seeking out healthcare providers who offer advanced treatments, including those based on cold plasma technology.

Additionally, the COVID-19 pandemic played a significant role in raising healthcare awareness regarding the importance of infection control and patient safety. Cold plasma's effectiveness in quickly and safely sterilizing surfaces and equipment became evident during the pandemic, further highlighting its relevance and prompting healthcare facilities to consider its adoption.

Key Market Challenges

Integration into Healthcare Workflows

Challenge facing the Cold Plasma in Healthcare market is the integration of cold plasma devices into existing healthcare workflows. While the technology holds immense promise, seamlessly incorporating it into the routines and practices of healthcare facilities presents several complexities. Healthcare institutions operate within well-established protocols and procedures, and any introduction of new technology must align with these workflows to ensure efficiency and effectiveness. The challenges of integration primarily revolve around the following aspects:

Firstly, healthcare facilities need to invest in the necessary infrastructure to accommodate cold plasma devices. This includes considerations such as space allocation, electrical requirements, and the integration of cold plasma equipment with existing medical equipment and systems. These changes can be resource-intensive and require careful planning.

Secondly, staff training is paramount. Healthcare professionals, from nurses to technicians and physicians, need to be proficient in operating and maintaining cold plasma devices. Training programs must be developed and implemented, and ongoing education is essential to keep healthcare providers updated on best practices.

Thirdly, the introduction of new technology can disrupt established workflows. Healthcare institutions must carefully manage this transition to minimize disruptions to patient care. This may involve temporarily parallel processes or gradual integration to ensure a smooth shift.

Lastly, there is a cost associated with the integration of cold plasma technology. Healthcare facilities must allocate budgets for equipment acquisition, staff training, and infrastructure improvements. This financial commitment can be a significant hurdle for some institutions, particularly smaller healthcare providers.

Cost of Implementation

Challenge in the Cold Plasma in Healthcare market is the cost of implementation. While the benefits of cold plasma technology are increasingly recognized, the initial financial investment required for its acquisition, integration, and operation can be a significant barrier for healthcare providers and institutions.

Firstly, the upfront cost of purchasing cold plasma equipment can be substantial. High-quality cold plasma devices are precision instruments with advanced technology, which often comes with a corresponding price tag. Smaller healthcare facilities or those with limited budgets may find it challenging to allocate resources for the initial purchase.

Secondly, beyond the acquisition cost, ongoing operational expenses must be considered. This includes maintenance, calibration, and regular servicing of the cold plasma devices to ensure they function optimally. Additionally, the cost of consumables, such as gas supplies, may add to the overall cost of implementation.

Furthermore, investments in infrastructure and facilities may be necessary to accommodate cold plasma technology. Modifications to existing healthcare environments to meet the electrical and spatial requirements of cold plasma equipment can contribute to the financial burden.

Healthcare providers must also allocate resources for staff training and education. Ensuring that healthcare professionals are proficient in using and maintaining cold plasma devices is essential for safe and effective operation.

Key Market Trends

Data-Driven Healthcare

Key trend in the Cold Plasma in Healthcare market centers around data-driven healthcare. This trend is marked by the integration of cold plasma devices with advanced data collection and analysis systems to enhance treatment precision and effectiveness.

In today's healthcare landscape, data is king. Cold plasma technology is no exception. Manufacturers are incorporating sensors and monitoring capabilities into cold plasma devices, allowing for real-time data collection during treatments. This data can include parameters like temperature, gas flow rates, and treatment duration. The information collected is then transmitted to centralized systems or cloud platforms, where it can be analyzed and interpreted.

The advantages of data-driven healthcare with cold plasma are significant. It enables healthcare providers to closely monitor and adjust treatments based on patient-specific data, optimizing therapeutic outcomes. For example, in wound healing, data-driven systems can assess tissue response to cold plasma treatment and make real-time adjustments to promote faster healing. In cancer treatment, treatment efficacy can be closely monitored, ensuring that the cold plasma precisely targets cancer cells while sparing healthy tissue.

Furthermore, the collected data can contribute to research and development efforts, facilitating continuous improvement in cold plasma technology and its applications in healthcare. It also supports evidence-based decision-making, which is crucial for gaining regulatory approvals and building trust among healthcare professionals.

This trend aligns with the broader movement toward digitalization in healthcare, offering increased treatment precision, patient safety, and the potential for more effective, personalized medical care. As data-driven approaches become more prevalent, they are expected to further solidify the role of cold plasma technology as a valuable tool in modern healthcare practices.

Personalized Medicine

Personalized medicine, within the context of the healthcare market, represents a transformative approach to patient care and treatment that tailors medical interventions to individual characteristics, needs, and genetic profiles. This trend is reshaping the Cold Plasma in Healthcare market by emphasizing precision and customization in the delivery of healthcare solutions. In personalized medicine, treatments and therapies are designed to align precisely with a patient's unique genetic makeup and medical history. This approach allows for more targeted and effective interventions, reducing the risk of adverse effects and optimizing therapeutic outcomes. For the Cold Plasma in Healthcare market, this means that cold plasma technology can be fine-tuned to suit the specific requirements of each patient, whether it's in wound healing, cancer treatment, or other applications. The demand for personalized medicine is on the rise as patients and healthcare providers increasingly seek treatments that are not only effective but also minimize side effects and maximize the likelihood of success. Cold plasma's adaptability and versatility make it well-suited to this trend, as it can be adjusted and optimized for individual patient needs. Furthermore, personalized medicine has the potential to drive research and development in the Cold Plasma in Healthcare market. As more data is collected on patient outcomes and treatment responses, it can inform the refinement of cold plasma technologies and their applications, resulting in more effective and patient-centric solutions.

Segmental Insights

Application Insights

The Wound Healing Segment dominates the Cold Plasma in Healthcare market and is predicted to continue expanding over the coming years. The dominance of the Wound Healing Segment in the Cold Plasma in Healthcare market can be attributed to several compelling factors, making it a frontrunner with continued expansion prospects. Firstly, chronic wounds, such as diabetic ulcers and pressure sores, pose a growing healthcare challenge globally. These conditions demand innovative and effective wound care solutions, and cold plasma technology has emerged as a promising answer. Cold plasma accelerates wound healing by stimulating cell proliferation, angiogenesis, and tissue regeneration while minimizing infection risk. This exceptional therapeutic capacity has garnered significant attention from healthcare providers and researchers. Secondly, as healthcare systems worldwide seek cost-effective and efficient solutions, the role of cold plasma in wound care gains prominence. By expediting the healing process and reducing the risk of complications, it not only improves patient outcomes but also contributes to cost savings in the long run. Healthcare institutions are increasingly recognizing the economic benefits of implementing cold plasma devices. Moreover, the COVID-19 pandemic underscored the importance of maintaining sterile healthcare environments and efficient wound care, further amplifying the demand for cold plasma solutions. Hospitals and clinics sought effective means of infection control and wound treatment, making cold plasma technology a critical asset in the healthcare landscape.

Regional Insights

The North America region has established itself as the leader in the Cold Plasma in Healthcare Market in 2022. Firstly, North America boasts a robust and well-established healthcare infrastructure, which includes cutting-edge medical facilities, research institutions, and a technologically advanced healthcare sector. This provides a conducive environment for the adoption and integration of innovative technologies like cold plasma into mainstream healthcare practices. Secondly, the region's heightened awareness of healthcare advancements and the importance of patient safety has driven the rapid adoption of cold plasma technology. Healthcare providers in North America are increasingly recognizing the benefits of cold plasma in sterilization, wound healing, and cancer treatment, particularly in the context of the COVID-19 pandemic. This has led to a surge in demand for cold plasma devices. Thirdly, North America's regulatory environment, while stringent, provides clear pathways for the approval and deployment of medical technologies. Regulatory agencies like the FDA in the United States have been actively engaged in assessing and approving cold plasma devices, giving healthcare providers confidence in their safety and efficacy. Moreover, collaborations between academia, industry, and healthcare providers in North America have fostered innovation and knowledge sharing, facilitating the development and implementation of cold plasma technology in diverse medical specialties.

Key Market Players

  • Neoplas med GmbH
  • U.S. Medical Innovations
  • Terumo Medical Corp
  • Adtec Plasma Technology Co Ltd
  • Apyx Medical Corp
  • Nordson Corp
  • Europlasma NV
  • Terraplasma GmbH
  • Henniker Plasma
  • Smith & Nephew plc

Report Scope:

In this report, the Cold Plasma in Healthcare Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cold Plasma in Healthcare Market, Application:

  • Wound Healing
  • Surgical Application
  • Other Medical Applications

Cold Plasma in Healthcare Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • Italy
  • France
  • Spain
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Cold Plasma in Healthcare Market.

Available Customizations:

  • Cold Plasma in Healthcare Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cold Plasma in Healthcare Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Wound Healing, Surgical Application and Other Medical Applications)
    • 5.2.2. By Region
    • 5.2.3. By Company (2022)
  • 5.3. Market Map

6. North America Cold Plasma in Healthcare Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cold Plasma in Healthcare Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
    • 6.3.2. Canada Cold Plasma in Healthcare Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
    • 6.3.3. Mexico Cold Plasma in Healthcare Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application

7. Europe Cold Plasma in Healthcare Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cold Plasma in Healthcare Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
    • 7.3.2. United Kingdom Cold Plasma in Healthcare Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
    • 7.3.3. Italy Cold Plasma in Healthcare Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Application
    • 7.3.4. France Cold Plasma in Healthcare Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
    • 7.3.5. Spain Cold Plasma in Healthcare Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application

8. Asia-Pacific Cold Plasma in Healthcare Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Cold Plasma in Healthcare Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
    • 8.3.2. India Cold Plasma in Healthcare Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
    • 8.3.3. Japan Cold Plasma in Healthcare Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
    • 8.3.4. South Korea Cold Plasma in Healthcare Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
    • 8.3.5. Australia Cold Plasma in Healthcare Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application

9. South America Cold Plasma in Healthcare Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cold Plasma in Healthcare Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
    • 9.3.2. Argentina Cold Plasma in Healthcare Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
    • 9.3.3. Colombia Cold Plasma in Healthcare Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application

10. Middle East and Africa Cold Plasma in Healthcare Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cold Plasma in Healthcare Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
    • 10.3.2. Saudi Arabia Cold Plasma in Healthcare Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
    • 10.3.3. UAE Cold Plasma in Healthcare Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions

13. Global Cold Plasma in Healthcare Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Treatment Types

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Neoplas med GmbH
    • 15.5.2. U.S. Medical Innovations
    • 15.5.3. Terumo Medical Corp
    • 15.5.4. Adtec Plasma Technology Co Ltd
    • 15.5.5. Apyx Medical Corp
    • 15.5.6. Nordson Corp
    • 15.5.7. Europlasma NV
    • 15.5.8. Terraplasma GmbH
    • 15.5.9. Henniker Plasma
    • 15.5.10. Smith & Nephew plc

16. Strategic Recommendations

17. About Us & Disclaimer

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦